NEW YORK, July 11 — A short seller’s fraud allegations against artificial intelligence company Blaize have triggered a formal investigation by the Rosen Law Firm, a prominent investor rights practice. The probe, announced on July 9, 2026, centers on whether the company issued materially misleading business information to the investing public. The trouble began on April 28, 2026, when Pelican Way Research published a report alleging that Blaize’s recent $50 million deal with a firm called NeoTensr is fraudulent.
The market reacted swiftly. Blaize stock tumbled 12% that same day, according to Investing.com, which first reported the story.
That single-day drop represents a significant market reaction to the allegations. For investors who bought shares before the short seller report, the losses were immediate and substantial. The Rosen Law Firm is now investigating whether Blaize executives knew about problems with the NeoTensr deal before the public did — and whether they failed to disclose those problems in regulatory filings or public statements.
What the investigation means
The Rosen investigation is still in its early stages. The firm has not filed a lawsuit, but it is gathering evidence and interviewing potential witnesses. The probe will examine the timeline of the NeoTensr deal, the nature of the relationship between Blaize and NeoTensr, and what company officials told investors about the transaction.
Short seller reports are a common feature of modern markets. Firms like Pelican Way Research make money when a stock falls, so their reports are inherently adversarial.
But the 12% stock drop on April 28 suggests that many investors found the allegations credible enough to sell first and ask questions later. The Rosen Law Firm has a track record of pursuing securities class actions against companies accused of misleading investors. Their involvement signals that at least one major investor rights firm believes there may be merit to the short seller’s claims.
What to watch next
The coming weeks will determine whether the Rosen investigation leads to a formal lawsuit. If the firm finds evidence that Blaize knowingly misled investors about the NeoTensr deal, shareholders who bought stock between the announcement of the deal and the short seller report could potentially recover losses. Blaize has not yet issued a public response to the Rosen investigation.
The company’s next quarterly filing with securities regulators will be closely watched for any restatements of revenue or disclosures about the NeoTensr transaction. For now, the central question remains unanswered: Was the $50 million NeoTensr deal legitimate, or was it, as Pelican Way Research alleges, fraudulent?
The Rosen investigation is the first step toward finding out.
